Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2014 (2014), Article ID 102184, 9 pages
http://dx.doi.org/10.1155/2014/102184
Review Article

Ethynilestradiol 20 mcg plus Levonorgestrel 100 mcg: Clinical Pharmacology

1Gynecological Endocrinology, Pathophysiology of Menopause and Osteoporosis, IDI-IRCCS, Via Monti di Creta 104, 00167 Rome, Italy
2Laboratory of Experimental Immunology, IDI-IRCCS, 00167 Rome, Italy

Received 1 July 2014; Accepted 27 October 2014; Published 16 November 2014

Academic Editor: Kevin Sinchak

Copyright © 2014 Stefano Lello and Andrea Cavani. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. E. Schindler, “Non-contraceptive benefits of oral hormonal contraceptives,” International Journal of Endocrinology and Metabolism, vol. 11, no. 1, pp. 41–47, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. F. P. Guengerich, “Inhibition of oral contraceptive steroid-metabolizing enzymes by steroids and drugs,” American Journal of Obstetrics and Gynecology, vol. 163, no. 6, pp. 2159–2163, 1990. View at Publisher · View at Google Scholar · View at Scopus
  3. P. R. O. de Montellano and K. L. Kunze, “Self-catalyzed inactivation of hepatic cytochrome P-450 by ethynyl substrates,” The Journal of Biological Chemistry, vol. 255, no. 12, pp. 5578–5585, 1980. View at Google Scholar · View at Scopus
  4. U. B. Lindberg, N. Crona, L. Stigendal, A. C. Teger-Nilsson, and G. Silfverstolpe, “A comparison between effects of estradiol valerate and low dose ethinyl estradiol on haemostasis parameters,” Thrombosis and Haemostasis, vol. 61, no. 1, pp. 65–69, 1989. View at Google Scholar · View at Scopus
  5. U.-B. Lindberg, L. Enk, N. Crona, and G. Silfverstolpe, “A comparison of the effects of ethinyl estradiol and estradiol valerate on serum and lipoprotein lipids,” Maturitas, vol. 10, no. 4, pp. 343–352, 1988. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Jung-Hoffmann, M. Fitzner, and H. Kuhl, “Oral contraceptives containing 20 or 30 μg ethinylestradiol and 150 μg desogestrel: Pharmacokinetics and pharmacodynamic parameters,” Hormone Research, vol. 36, no. 5-6, pp. 238–246, 1991. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Fotherby and A. D. S. Caldwell, “New progestogens in oral contraception,” Contraception, vol. 49, no. 1, pp. 1–32, 1994. View at Publisher · View at Google Scholar · View at Scopus
  8. D. J. Back, S. F. M. Grimmer, S. Rogers, P. J. Stevenson, and M. L. Orme, “Comparative pharmacokinetics of levonorgestrel and ethinyloestradiol following intravenous, oral and vaginal administration,” Contraception, vol. 36, no. 4, pp. 471–479, 1987. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Z. Stanczyk, “Structure-function relationships, potency, and pharmacokinetics of progestogens,” in Treatment of the Postmenopausal Woman: Basic and Clinical Aspects, R. A. Lobo, Ed., pp. 69–89, Raven Press, New York, NY, USA, 1994. View at Google Scholar
  10. F. Z. Stanczyk and S. Roy, “Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids,” Contraception, vol. 42, no. 1, pp. 67–96, 1990. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Juchem, K. Pollow, W. Elger, G. Hoffmann, and V. Mobus, “Receptor binding of norgestimate—a new orally active synthetic progestational compound,” Contraception, vol. 47, no. 3, pp. 283–294, 1993. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Kuhl, “Comparative pharmacology of newer progestogens,” Drugs, vol. 51, no. 2, pp. 188–215, 1996. View at Publisher · View at Google Scholar · View at Scopus
  13. A. E. Schindler, C. Campagnoli, R. Druckmann et al., “Classification and pharmacology of progestins,” Maturitas, vol. 46, supplement 1, pp. S7–S16, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. G. V. Upton and A. Corbin, “The relevance of the parmacologic properties of a progestational agent to its clinical effects as a combination oral contraceptive,” Yale Journal of Biology and Medicine, vol. 62, no. 5, pp. 445–457, 1989. View at Google Scholar · View at Scopus
  15. I. Wiegratz and H. Kuhl, “Progestogen therapies: differences in clinical effects?” Trends in Endocrinology and Metabolism, vol. 15, no. 6, pp. 277–285, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Endrikat, H. Blode, C. Gerlinger, P. Rosenbaum, and W. Kuhnz, “A pharmacokinetic study with a low-dose oral contraceptive containing 20 μg ethinylestradiol plus 100 μg levonorgestrel,” European Journal of Contraception and Reproductive Health Care, vol. 7, no. 2, pp. 79–90, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. M. I. Wilde and J. A. Balfour, “Gestodene—a review of its pharmacology, efficacy and tolerability in combined contraceptive preparations,” Drugs, vol. 50, no. 2, pp. 364–395, 1995. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Spona, W. Feichtinger, C. Kindermann, C. Wünsch, and K. Brill, “Inhibition of ovulation by an oral contraceptive containing 100 μg levonorgestrel in combination with 20 μg ethinylestradiol,” Contraception, vol. 54, no. 5, pp. 299–304, 1996. View at Publisher · View at Google Scholar · View at Scopus
  19. H. J. Hoogland and S. O. Skouby, “Ultrasound evaluation of ovarian activity under oral contraceptives,” Contraception, vol. 47, no. 6, pp. 583–590, 1993. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Coney and A. Delconte, “The effects on ovarian activity of a monophasic oral contraceptive with 100 μg levonorgestrel and 20 μg ethinyl estradiol,” American Journal of Obstetrics and Gynecology, vol. 181, no. 5, pp. S53–S58, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. R. L. Young and A. Delconte, “Effects of low-dose monophasic levonorgestrel with ethinyl estradiol preparation on serum lipid levels: a twenty-four month clinical trial,” American Journal of Obstetrics & Gynecology, vol. 181, no. 5, pp. S59–S62, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Reisman, D. Martin, and M. J. Gast, “A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 μg levonorgestrel with 20 μg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol,” American Journal of Obstetrics and Gynecology, vol. 181, no. 5, pp. S45–S52, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. S. O. Skouby, J. Endrikat, B. Düsterberg et al., “A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 μg ethinyl estradiol combined with 100 μg levonorgestrel,” Contraception, vol. 71, no. 2, pp. 111–117, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Endrikat, C. Klipping, M. Cronin et al., “An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables,” Contraception, vol. 65, no. 3, pp. 215–221, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Lello, G. Vittori, A. M. Paoletti, R. Sorge, F. Guardianelli, and G. B. Melis, “Effects on body weight and body composition of a low-dose oral estroprogestin containing ethinyl estradiol 20 μg plus levonorgestrel 100 μg,” Gynecological Endocrinology, vol. 23, no. 11, pp. 632–637, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Endrikat, R. Hite, R. Bannemerschult, C. Gerlinger, and W. Schmidt, “Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 μg ethinylestradiol/100 μg levonorgestrel and 20 μg ethinylestradiol/500 μg norethisterone,” Contraception, vol. 64, no. 1, pp. 3–10, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. M. J. Rosenberg, M. S. Waugh, and T. E. Meehan, “Use and misuse of oral-contraceptives: risk indicators for poor pill taking and discontinuation,” Contraception, vol. 51, no. 5, pp. 283–288, 1995. View at Publisher · View at Google Scholar · View at Scopus
  28. W. F. Pratt and C. A. Bachrach, “What do women use when they stop using the pill?” Family Planning Perspectives, vol. 19, no. 6, pp. 257–266, 1987. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Rosenberg, “Weight change with oral contraceptive use and during the menstrual cycle: results of daily measurements,” Contraception, vol. 58, no. 6, pp. 345–349, 1998. View at Publisher · View at Google Scholar · View at Scopus
  30. R. C. Hite, R. Bannemerschult, P. Fox-Kuchenbecker, R. Turck, and K. Brill, “Large observational trial of a new low-dose oral contraceptive containing 20 μg ethinylestradiol and 100 μg levonorgestrel (Miranova) in Germany,” The European Journal of Contraception and Reproductive Health Care, vol. 4, no. 1, pp. 7–13, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Coney, K. Washenik, R. G. B. Langley, J. J. DiGiovanna, and D. D. Harrison, “Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials,” Contraception, vol. 63, no. 6, pp. 297–302, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Thiboutot, D. F. Archer, A. Lemay, K. Washenik, J. Roberts, and D. D. Harrison, “A randomized, controlled trial of a low-dose contraceptive containing 20 μg of ethinyl estradiol and 100 μg of levonorgestrel for acne treatment,” Fertility and Sterility, vol. 76, no. 3, pp. 461–468, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. D. F. Archer, R. Maheux, A. DelConte, and F. B. O'Brien, “A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group (NALSG),” Contraception, vol. 55, no. 3, pp. 139–144, 1997. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Bannemerschult, J. P. Hanker, C. Wünsch, P. Fox, M. Albring, and K. Brill, “A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel over six treatment cycles,” Contraception, vol. 56, no. 5, pp. 285–290, 1997. View at Publisher · View at Google Scholar · View at Scopus
  35. D. F. Archer, R. Maheux, A. DelConte, and F. B. O'Brien, “Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 μg levonorgestrel and 20 μg ethinyl estradiol (Alesse),” American Journal of Obstetrics and Gynecology, vol. 181, no. 5, pp. S39–S44, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. D. F. Archer, E. F. Mammen, and G. S. Grubb, “The effects of a low-dose monophasic preparation of levonorgestrel and ethinyl estradiol on coagulation and other hemostatic factors,” The American Journal of Obstetrics and Gynecology, vol. 181, no. 5, pp. S63–S66, 1999. View at Publisher · View at Google Scholar · View at Scopus
  37. D. W. Barritt and S. C. Jordan, “Clinical features of pulmonary embolism,” The Lancet, vol. 277, no. 7180, pp. 729–733, 1961. View at Publisher · View at Google Scholar · View at Scopus
  38. T. M. Farley, J. Collins, and J. J. Schlesselman, “Hormonal contraception and risk of cardiovascular disease. An international perspective,” Contraception, vol. 57, pp. 211–230, 1998. View at Google Scholar
  39. R. D. T. Farmer, R. A. Lawrenson, J.-C. Todd et al., “A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives,” British Journal of Clinical Pharmacology, vol. 49, no. 6, pp. 580–590, 2000. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Jick, S. S. Jick, V. Gurewich, M. W. Myers, and C. Vasilakis, “Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components,” The Lancet, vol. 346, no. 8990, pp. 1589–1593, 1995. View at Publisher · View at Google Scholar · View at Scopus
  41. S. S. Jick and R. K. Hernandez, “Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data,” British Medical Journal, vol. 342, no. 7804, Article ID d2151, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. Ø. Lidegaard, E. Løkkegaard, A. L. Svendsen, and C. Agger, “Hormonal contraception and risk of venous thromboembolism: national follow-up study,” BMJ, vol. 339, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. Ø. Lidegaard, L. H. Nielsen, C. W. Skovlund, F. E. Skjeldestad, and E. Løkkegaard, “Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: danish cohort study, 2001–9,” British Medical Journal, vol. 343, Article ID d6423, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Parkin, K. Sharples, R. K. Hernandez, and S. S. Jick, “Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database,” British Medical Journal, vol. 342, no. 7804, Article ID d2139, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Van Hylckama Vlieg, F. M. Helmerhorst, J. P. Vandenbroucke, C. J. M. Doggen, and F. R. Rosendaal, “The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study,” British Medical Journal, vol. 339, no. 7720, article 561, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. O. Lidegaard, L. H. Nielsen, C. W. Skovlund, and E. Løkkegaard, “Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001–10,” The British Medical Journal, vol. 344, Article ID e2990, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Blanco-Molina and M. Monreal, “Venous thromboembolism in women taking hormonal contraceptives,” Expert Review of Cardiovascular Therapy, vol. 8, no. 2, pp. 211–215, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. S. N. Tchaikovski and J. Rosing, “Mechanisms of estrogen-induced venous thromboembolism,” Thrombosis Research, vol. 126, no. 1, pp. 5–11, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. J. C. Dinger, L. A. J. Heinemann, and D. Kühl-Habich, “The safety of a drospirenone-containing oral contraceptive: final results from the European active surveillance study on oral contraceptives based on 142,475 women-years of observation,” Contraception, vol. 75, no. 5, pp. 344–354, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. J. D. Seeger, J. Loughlin, P. M. Eng, C. R. Clifford, J. Cutone, and A. M. Walker, “Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives,” Obstetrics and Gynecology, vol. 110, no. 3, pp. 587–593, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. J. Dinger, S. Möhner, and K. Heinemann, “Cardiovascular risk associated with the use of an etonogestrel-containing vaginal ring,” Obstetrics and Gynecology, vol. 122, no. 4, pp. 800–808, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Sidney, T. C. Cheetham, F. A. Connell et al., “Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users,” Contraception, vol. 87, no. 1, pp. 93–100, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. N. Dunn, “Oral contraceptives and venous thromboembolism,” British Medical Journal, vol. 339, no. 7720, Article ID b3164, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. I. H. Thorneycroft, F. Z. Stanczyk, K. D. Bradshaw, S. A. Ballagh, M. Nichols, and M. E. Weber, “Effect of low-dose oral contraceptives on androgenic markers and acne,” Contraception, vol. 60, no. 5, pp. 255–262, 1999. View at Publisher · View at Google Scholar · View at Scopus
  55. WHO, Cardiovascular Disease and Steroid Hormone Contraception, World Health Organization (WHO), Geneva, Switzerland, 1998.
  56. WHO, “Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study,” The Lancet, vol. 346, no. 8990, pp. 1575–1582, 1995. View at Publisher · View at Google Scholar · View at Scopus
  57. European Medicines Agency Position Statement, “CPMP concludes its assessment of “third generation” combined oral contraceptives and risk of venous thromboembolism,” Tech. Rep. EMEA/CPMP/2250/01, 2001. View at Google Scholar
  58. European Medicines Agency, “Guidelines on clinical investigation of steoird contraceptives in women,” Doc. Ref. EMEA/CPMP/519/98 Rev 1, 2005. View at Google Scholar
  59. Pharmacovigilance Working Party May 2011 plenary meeting. EMA/CHMP/PhVWP/394737/2011, 2011.
  60. European Medicines Agency, “Pharmacovigilance risk assessment committee (PRAC) October 2013,” Tech. Rep. EMA/607314/2013, EMA, 2013. View at Google Scholar
  61. Ø. Lidegaard, E. Løkkegaard, A. Jensen, C. W. Skovlund, and N. Keiding, “Thrombotic stroke and myocardial infarction with hormonal contraception,” The New England Journal of Medicine, vol. 366, no. 24, pp. 2257–2266, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. C. W. Wallwiener, L. M. Wallwiener, H. Seeger, A. O. Mück, J. Bitzer, and M. Wallwiener, “Prevalence of sexual dysfunction and impact of contraception in female German medical students,” Journal of Sexual Medicine, vol. 7, no. 6, pp. 2139–2148, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Bancroft, B. B. Sherwin, G. M. Alexander, D. W. Davidson, and A. Walker, “Oral contraceptives, androgens, and the sexuality of young women: II. The role of androgens,” Archives of Sexual Behavior, vol. 20, no. 2, pp. 121–135, 1991. View at Publisher · View at Google Scholar · View at Scopus
  64. C. A. Graham, J. Bancroft, H. A. Doll, T. Greco, and A. Tanner, “Does oral contraceptive-induced reduction in free testosterone adversely affect the sexuality or mood of women?” Psychoneuroendocrinology, vol. 32, no. 3, pp. 246–255, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. C. M. H. Coenen, C. M. G. Thomas, G. F. Borm, J. M. G. Hollanders, and R. Rolland, “Changes in androgens during treatment with four low-dose contraceptives,” Contraception, vol. 53, no. 3, pp. 171–176, 1996. View at Publisher · View at Google Scholar · View at Scopus
  66. S. Sarajari, D. Wickam, C. Marin, and J. Berman, “Pilot Study assessing the impact of hormonal contraceptives on serum testosterone levels and sexual functions in pre-menopausal women,” Fertility and Sterility, vol. 82, pp. S78–S79, 2004. View at Google Scholar
  67. C. Panzer, S. Wise, G. Fantini et al., “Impact of oral contraceptives on sex hormone-binding globulin and androgen levels: a retrospective study in women with sexual dysfunction,” Journal of Sexual Medicine, vol. 3, no. 1, pp. 104–113, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. T. Greco, C. A. Graham, J. Bancroft, A. Tanner, and H. A. Doll, “The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 μg of ethinyl estradiol,” Contraception, vol. 76, no. 1, pp. 8–17, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. J. E. Shepherd, “Therapeutic options in female sexual dysfunction,” Journal of American Pharmacists Association, vol. 42, pp. 479–478, 2002. View at Google Scholar
  70. R. Strufaldi, L. M. Pompei, M. L. Steiner et al., “Effects of two combined hormonal contraceptives with the same composition and different doses on female sexual function and plasma androgen levels,” Contraception, vol. 82, no. 2, pp. 147–154, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. M. J. Rosenberg, A. Meyers, and V. Roy, “Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 μg and 35 μg estrogen preparations,” Contraception, vol. 60, no. 6, pp. 321–329, 1999. View at Publisher · View at Google Scholar · View at Scopus